Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial

This publication has 17 references indexed in Scilit:

• The Desmoteplase in Acute Ischemic Stroke (DIAS) Clinical Trial Program
  International Journal of Stroke, 2012
• Vascular Occlusion Enables Selecting Acute Ischemic Stroke Patients for Treatment With Desmoteplase
  Stroke, 2012
• Desmoteplase: discovery, insights and opportunities for ischaemic stroke
  British Journal of Pharmacology, 2011
• Pretreatment Diffusion- and Perfusion-MR Lesion Volumes Have a Crucial Influence on Clinical Response to Stroke Thrombolysis
  Journal of Cerebral Blood Flow & Metabolism, 2010
• Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study
  The Lancet Neurology, 2009
• Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
  New England Journal of Medicine, 2008
• The MRA-DWI Mismatch Identifies Patients With Stroke Who Are Likely to Benefit From Reperfusion
  Stroke, 2008
• Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS)
  Stroke, 2006
• The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)
  Stroke, 2005
• Tissue Plasminogen Activator for Acute Ischemic Stroke
  New England Journal of Medicine, 1995